Superworth

Sanara MedTech price to free cash flow SMTI

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026
66.9×
10-year median
44.0×
Against its 10-year history
61st
percentile: 0 is its lowest day, 100 its highest
10-year range
12.1× to 475×
Peer median
16.0×

Sanara MedTech's price to free cash flow is 66.9× as of Oct 23, 2026.

That is above its ten-year median of 44.0×, close to the middle of its last ten years.

Over that time it ranged from 12.1× in Nov 2017 to 475× in Jun 2019.

The median for 10 medical instruments and supplies stocks of a similar size is 16.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far66.9×56.5×92.6×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019475×17.6×475×
201817.6×13.2×461×
201714.5×12.1×37.6×

Against its peers

Companies in Medical - Instruments & Supplies nearest Sanara MedTech's size, closest first, today.

CompanyPrice to free cash flow
SMTISanara MedTech66.9×
INFUInfuSystem12.1×
EMBCEmbecta2.3×
UTMDUtah Medical Products20.6×
PDEXPro DEX29.5×
TCMDTactile Systems Technology20.0×
MDXGMimedxn/m
MOVMovado9.8×
KEQUKewaunee Scientific8.7×
IRMDIradimed43.7×
STAAStaar Surgicaln/m
Peer median16.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Sanara MedTech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.